Medicenna secures new U.S. patents across IL-2, IL-4 and IL-13 platforms
Medicenna Therapeutics has announced two newly issued U.S. patents and one allowed patent application covering its IL-4 and IL-13 Superkine platforms, extending intellectual property protection to applications including cellular immunotherapy and combination treatment of central nervous system tumours. The Toronto-listed company says the grants, together with recent awards in Australia and Canada, bring its global portfolio to more than 100 active patents and applications.
The two issued patents address distinct biological constructs. U.S. Patent No. 12,503,496, co-owned with the U.S. National Institutes of Health, covers IL-4 Superkine fusion proteins applied to cellular immunotherapy. U.S. Patent No. 12,590,133, in-licensed from Stanford University, is directed to IL-13 Superkine immune cell targeting constructs, vectors, and engineered cells, with grants now in place in both the United States and China. The allowed application, once issued, will cover combination therapy using bizaxofusp alongside VEGF-A-directed agents for CNS tumours, with pending filings across six additional jurisdictions including Europe, Japan, and South Korea.
Clinical backdrop
Bizaxofusp, previously known as MDNA55, is Medicenna's lead clinical asset. It has been studied across five clinical trials enrolling more than 130 patients, including a Phase 2b study in recurrent glioblastoma, a form of brain cancer with no standard curative option. The candidate holds FDA Fast Track and both FDA and EMA Orphan Drug designations. The two other programmes protected by this latest patent activity are MDNA11, a long-acting IL-2 Superkine designed to preferentially stimulate effector T cells and NK cells without triggering the IL-2 receptor alpha subunit, and MDNA113, a PD-1 x IL-2 bispecific in development for solid tumours.
Fahar Merchant, President and Chief Executive Officer, said the grants "extend protection into important new applications, including cellular immunotherapy and combination treatment of CNS tumors," and described the overall estate as one he believes is among the most comprehensive in Superkine-based immunotherapy.
Market context
The cytokine engineering field has grown considerably more competitive over the past three years. Several companies are pursuing next-generation IL-2 variants specifically engineered to separate therapeutic efficacy from dose-limiting toxicity, an approach Medicenna's MDNA11 also targets via its CD25-null design. In parallel, the intersection of IL-4 and IL-13 biology with CAR-T and other cell therapy modalities is attracting increasing interest from larger pharmaceutical groups, making defensive patent positions in these receptor systems commercially meaningful beyond Medicenna's own development programmes.
Securing parallel grants in Australia and Canada alongside the U.S. milestones also matters for out-licensing conversations, since a geographically coherent estate reduces the friction for potential partners evaluating global commercial rights. Medicenna has not announced a licensing deal or partnership in conjunction with this announcement.
The next substantive milestones for investors to watch will be clinical updates from the bizaxofusp and MDNA11 programmes rather than further patent grants. Any Phase 2b data readout or regulatory interaction on the GBM programme in particular is likely to carry more weight in the market than IP estate expansion, however strategically important the latter is for long-term asset value.